Emcure Pharmaceuticals, in partnership with Novo Nordisk India, launched Poviztra® semaglutide injection to expand weight-loss treatment options in India. As a second brand of Wegovy®, Poviztra will leverage Emcure’s distribution to reach wider markets. The launch underscores a strategic push to address India’s rising obesity burden with innovative therapies.
Emcure Pharmaceuticals Ltd, in collaboration with Novo Nordisk India, has officially launched Poviztra®, a semaglutide-based injection, in the Indian market. This marks a significant milestone in addressing the growing demand for advanced weight-loss therapies in the country.
Strategic Partnership
-
Novo Nordisk India partnered with Pune-based Emcure to expand the reach of semaglutide, marketed globally under the brand Wegovy®.
-
Poviztra will serve as a second brand of Wegovy®, ensuring broader accessibility across India.
Therapeutic Impact
-
Semaglutide, administered as a 2.4 mg injection, has been clinically proven to aid weight management by regulating appetite and reducing calorie intake.
-
The drug is particularly targeted at individuals struggling with obesity, a condition affecting nearly 135 million Indians.
Market Expansion
-
Emcure’s strong distribution network will help extend availability beyond metro cities, reaching pharmacies and healthcare providers in underserved regions.
-
The launch is expected to accelerate India’s adoption of modern anti-obesity treatments, complementing lifestyle interventions.
Executives from both companies emphasized that Poviztra represents not just a product launch but a commitment to tackling India’s obesity challenge through innovation and accessibility.
Sources: Emcure Pharmaceuticals Press Release, Fortune India, Financial Express